🇺🇸 FDA
Patent

US 10421765

Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase

granted A61PA61P35/00

Quick answer

US patent 10421765 (Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase) held by The Board of Regents of the University of Texas System expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
39
CPC classes
A61P, A61P35/00